When EMA and FDA decisions conflict: differences in patients or in regulation?

@article{Wolfe2013WhenEA,
  title={When EMA and FDA decisions conflict: differences in patients or in regulation?},
  author={Sidney M. Wolfe},
  journal={BMJ : British Medical Journal},
  year={2013},
  volume={347}
}
  • Sidney M. Wolfe
  • Published 2013
  • Medicine
  • BMJ : British Medical Journal
  • In his new regular column Sid Wolfe asks why the two regulatory bodies have arrived at different decisions on the same diet drugs 

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 13 CITATIONS

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 12 REFERENCES

    Withdrawal of sibutramine in Europe

    Elevated heart rate: a "new" cardiovascular risk factor?

    22529: lorcaserin hydrochloride tablets, 10 mg [FDA briefing document for 10 May 2012 advisory committee meeting

    • Fda, Nda

    Advisory Committee meeting for phentermine/topiramate (Qnexa) [briefing memo

    • E Colman

    Application number 022529Orig1s000: approval letter

    Clinical briefing document: Endocrinologic and Metabolic Drugs Advisory Committee meeting

    FDA approves weight-management drug Qsymia

    Medications target long-term weight control